Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices

Reuters

Mar 11

<a href="https://laohu8.com/S/FEMY">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices

Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618095211"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618095211\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618095211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618095211","market":"nz","top_or_hot":-1,"title":"Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFemasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a>. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL730kY9:1","article_id":"2618095211","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618095211","pubTimestamp":1773158955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4082":"医疗保健设备","BK4539":"次新股","FEMY":"Femasys Inc"},"translate_title":"Femasys Inc.发布有关女性生殖健康设备的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEMY":0.9},"content_text":"Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices\n    \n\n        Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}